Yimmugo, which was introduced in Europe at the end of 2022, could be on the market in the US within months.
Patrick Lavery
Advertisement
Patrick Lavery is an Editor for the MJH Life Sciences brands Pharmaceutical Technology and BioPharm International, and their respective websites, pharmtech.com and biopharminternational.com. Previously at MJH, he filled the same role for LCGC International and Spectroscopy.
Articles by Patrick Lavery
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Lilly Launches UK Trial of Weight-Loss Drug as US Price Drops
2
Batch Certification for New Manufacturing Technologies: The Qualified Person Role in a Digital Environment
3
FDA Deploys Agentic AI Capabilities for Agency Staff
4
BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation
5
